The Lancet10d
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Lack of diversity in clinical trials is leaving women and patients of color behind and harming the future of medicine – Podcast
Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different genders, races, ages and life histories, chances ...
appliedclinicaltrialsonline3d
Replacing Anecdotal With Empirical Evidence On Impact of DCTs
Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...
The Lancet11d
Applying the estimand framework to inflammatory bowel disease clinical trials
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...
FierceBiotech11d
GI-focused CRO Alimentiv ups trial tech with PhaseV’s adaptive machine learning software
Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology ...
Medical Xpress29d
Clinical trial advances research in treatment of biliary tract cancers
The study was the first Phase III clinical ... difference in the average length of time the patient survived after diagnosis with advanced, inoperable biliary tract cancer," Shroff said. "Our ...
Business Insider15d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Based on the strength of these Phase ... Both clinical doses demonstrated improvement relative to placebo over 52 weeks, with the 50 mg dose showing a greater treatment effect. Additional analyses are ...
appliedclinicaltrialsonline4d
Phase III REGENCY Trial Confirms Gazyva/Gazyvaro Significantly Improves Kidney Outcomes in Lupus Nephritis Patients
Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing ...
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety Results Consistent with Safety Profile for ...
Healio9d
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Global study identifies markers for the five clinical stages of Parkinson's disease
From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...